[Translation] A single-center, open-label, randomized, single-dose, two-period, double-crossover bioequivalence study of metformin and empagliflozin tablets (VI) in healthy subjects under fasting and fed conditions
主要目的
比较空腹和餐后给药条件下,石家庄市普力制药有限公司提供的二甲双胍恩格列净片(VI)(每片含盐酸二甲双胍1000mg与恩格列净12.5mg)与Boehringer Ingelheim International GmbH持证的二甲双胍恩格列净片(VI)(每片含盐酸二甲双胍1000mg与恩格列净12.5mg,商品名:欧双静®)在健康成年人群中吸收程度和速度的差异,评价其生物等效性。
次要目的
评价空腹和餐后给药条件下,石家庄市普力制药有限公司提供的二甲双胍恩格列净片(VI)(每片含盐酸二甲双胍1000mg与恩格列净12.5mg)与Boehringer Ingelheim International GmbH持证的二甲双胍恩格列净片(VI)(每片含盐酸二甲双胍1000mg与恩格列净12.5mg,商品名:欧双静®)在健康成年人群中的安全性。
[Translation] Main purpose
To compare the differences in absorption extent and speed between metformin empagliflozin tablets (VI) provided by Shijiazhuang Puli Pharmaceutical Co., Ltd. (each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin) and metformin empagliflozin tablets (VI) certified by Boehringer Ingelheim International GmbH (each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin, trade name: Oushuangjing®) in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence.
Secondary objective
To evaluate the safety of metformin empagliflozin tablets (VI) (each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin) provided by Shijiazhuang Puli Pharmaceutical Co., Ltd. and metformin empagliflozin tablets (VI) (each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin, trade name: Oushuangjing®) certified by Boehringer Ingelheim International GmbH in healthy adults under fasting and postprandial administration conditions.